Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
J Endocrinol Invest ; 44(5): 957-968, 2021 May.
Article in English | MEDLINE | ID: mdl-32894472

ABSTRACT

PURPOSE: Gender differences in patients diagnosed with non-functioning Pituitary Adenomas (NFPA) in a National Referral Center for Pituitary Tumors at the Federico II University of Naples, Italy. METHODS: Patients newly diagnosed with non-functioning sellar masses found on pituitary Magnetic Resonance Imaging from January 1st 2016 to December 31th 2018 underwent anthropometric measurements, basal evaluation of pituitary function, and metabolic assessment. Fatty live index (FLI) and visceral adiposity index (VAI) were calculated. RESULTS: Seventy-three patients (35 males, 51.1 ± 17.0 years; 38 females, 41.8 ± 18.1 years) presented with NFPA. Lesions > 1 cm (85.7% vs. 47.3%; χ2 = 10.26, p = 0.001) and hypopituitarism (77.1% vs. 7.9%; χ2 = 33.29, p = 0.001) were more frequent in males than females. The highest sizes of pituitary adenomas were significantly associated with male gender (OR = 1.05, p = 0.049; R2 = 0.060; IC 1.00-1.10). Headache (62.8% vs. 31.6%; χ2 = 5.96, p = 0.015) and visual field deficits (57.1% vs. 26.3%; χ2 = 5.93, p = 0.015) were significantly more frequent in males than in females. There was no sex difference in obesity prevalence, but the metabolic syndrome was more common among males than females (60.6% vs. 26.3%; χ2 = 7.14, p = 0.001). FLI was also higher in males (69.6 ± 27.3 vs. 49.2 ± 31.3; p < 0.001), while there were no differences in VAI. CONCLUSIONS: Apart from the possible delay in the diagnosis induced by the gender differences in symptom presentation, the higher prevalence of macroadenomas amongst NFPA in males compared with females let to hypothesize a key role of the sex hormone profile as predictive factors of their biological behavior and metabolic profile. Further studies are, however, mandatory to better support the influence of gender differences on onset, progression, and metabolic consequences of NFPA.


Subject(s)
Adenoma , Intra-Abdominal Fat , Metabolic Syndrome , Obesity , Pituitary Neoplasms , Adenoma/epidemiology , Adenoma/metabolism , Adenoma/pathology , Adenoma/physiopathology , Aged , Asymptomatic Diseases/epidemiology , Female , Gonadal Steroid Hormones/analysis , Humans , Italy/epidemiology , Magnetic Resonance Imaging/methods , Male , Metabolic Syndrome/diagnosis , Metabolic Syndrome/epidemiology , Middle Aged , Obesity/diagnosis , Obesity/epidemiology , Pituitary Gland/diagnostic imaging , Pituitary Gland/pathology , Pituitary Neoplasms/epidemiology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , Sex Factors , Symptom Assessment/methods , Symptom Assessment/statistics & numerical data , Tertiary Care Centers/statistics & numerical data , Tumor Burden
2.
Nutr Metab Cardiovasc Dis ; 29(4): 319-324, 2019 04.
Article in English | MEDLINE | ID: mdl-30782507

ABSTRACT

AIMS: The nutritional management of renal transplant recipients (RTR) represents a complex problem either because the recovery of renal function is not complete and for the appearance of "unavoidable" metabolic side effects of immunosuppressive drugs. Nevertheless, it remains a neglected problem, whereas an appropriate dietary intervention could favorably affect graft survival. DATA SYNTHESIS: Renal transplantation is associated with steroids and calcineurin inhibitors administration, liberalization of diet after dialysis restrictions, and patients' better quality of life. These factors predispose, from the first months after surgery, to body weight gain, enhanced post transplant diabetes, hyperlipidemia, metabolic syndrome, with negative consequences on graft outcome. Unfortunately, specific guidelines about this topic and nutritional counseling are scarce; moreover, beyond the low adherence of patients to any dietary plan, there is a dangerous underestimation of the problem by physicians, sometimes with inadequate interventions. A prompt and specific nutritional management of RTR can help prevent or minimize these metabolic alterations, mostly when associated with careful and repeated counseling. CONCLUSIONS: A correct nutritional management, possibly tailored to enhance patients' motivation and adherence, represents the best preventive maneuver to increase patients' life and probably improve graft survival, at no cost and with no side effects.


Subject(s)
Graft Survival , Kidney Transplantation , Nutrition Disorders/prevention & control , Nutrition Therapy/methods , Nutritional Status , Diet, Healthy , Humans , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Nutrition Disorders/etiology , Nutrition Disorders/physiopathology , Quality of Life , Risk Factors , Time Factors , Treatment Outcome
3.
AJNR Am J Neuroradiol ; 38(12): 2264-2269, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29051208

ABSTRACT

BACKGROUND AND PURPOSE: The pulvinar sign refers to exclusive T1WI hyperintensity of the lateral pulvinar. Long considered a common sign of Fabry disease, the pulvinar sign has been reported in many pathologic conditions. The exact incidence of the pulvinar sign has never been tested in representative cohorts of patients with Fabry disease. The aim of this study was to assess the prevalence of the pulvinar sign in Fabry disease by analyzing T1WI in a large Fabry disease cohort, determining whether relaxometry changes could be detected in this region independent of the pulvinar sign positivity. MATERIALS AND METHODS: We retrospectively analyzed brain MR imaging of 133 patients with Fabry disease recruited through specialized care clinics. A subgroup of 26 patients underwent a scan including 2 FLASH sequences for relaxometry that were compared with MRI scans of 34 healthy controls. RESULTS: The pulvinar sign was detected in 4 of 133 patients with Fabry disease (3.0%). These 4 subjects were all adult men (4 of 53, 7.5% of the entire male population) with renal failure and under enzyme replacement therapy. When we tested for discrepancies between Fabry disease and healthy controls in quantitative susceptibility mapping and relaxometry maps, no significant difference emerged for any of the tested variables. CONCLUSIONS: The pulvinar sign has a significantly lower incidence in Fabry disease than previously described. This finding, coupled with a lack of significant differences in quantitative MR imaging, allows hypothesizing that selective involvement of the pulvinar is a rare neuroradiologic sign of Fabry disease.


Subject(s)
Fabry Disease/pathology , Pulvinar/pathology , Adolescent , Adult , Aged , Fabry Disease/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Pulvinar/diagnostic imaging , Retrospective Studies , Young Adult
4.
Clin Genet ; 86(4): 301-9, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24645664

ABSTRACT

Fabry disease (FD) is an X-linked disease in which mutations of the GLA gene result in a deficiency of the enzyme α-galactosidase A and subsequent progressive, intralysosomal deposition of undegraded glycosphingolipid products, primarily globotriaosylceramide, in multiple organs. Progressive nephropathy is one of the main features of FD and is marked by an insidious development, with an overall rate of progression of chronic kidney disease (CKD) very similar to diabetic nephropathy. Untreated patients usually develop end stage renal disease in their 50s. The decline in renal function in FD is adversely affected by male gender, advanced CKD, hypertension and, in particular, severe proteinuria. Enzyme replacement therapy (ERT) has been shown to slow the progression of Fabry nephropathy. The current consensus is that ERT should be started in all men and women with signs of renal involvement.


Subject(s)
Enzyme Replacement Therapy , Fabry Disease/genetics , Renal Insufficiency, Chronic/genetics , alpha-Galactosidase/genetics , Disease Progression , Fabry Disease/complications , Fabry Disease/pathology , Fabry Disease/therapy , Glycosphingolipids/metabolism , Humans , Kidney/metabolism , Kidney/pathology , Renal Insufficiency, Chronic/etiology , Renal Insufficiency, Chronic/pathology , Renal Insufficiency, Chronic/therapy , alpha-Galactosidase/metabolism
5.
JIMD Rep ; 9: 41-48, 2013.
Article in English | MEDLINE | ID: mdl-23430546

ABSTRACT

Anderson-Fabry disease (AFD) is a multiorgan X-linked lysosomal storage disease that particularly affects the heart, kidneys, and cerebrovascular system. Current treatment is enzyme replacement therapy (ERT) with agalsidase beta (Fabrazyme(®), Genzyme Corporation, Cambridge, MA, USA) or agalsidase alfa (Replagal(®), Shire Human Genetic Therapies AB, Lund, Sweden). It was recommended that patients switch to agalsidase alfa due to a manufacturing shortage of agalsidase beta beginning in June 2009. This study assessed the effect of switching to agalsidase alfa on clinical outcomes in patients with AFD previously treated with agalsidase beta. Ten patients (seven male, three female) with genetically confirmed AFD and at least 48 months' continuous data collected during treatment with agalsidase beta 1 mg/kg every other week were switched to agalsidase alfa 0.2 mg/kg every other week for at least 20 months, with prospective clinical evaluations every 6 months. Pre-switch data was collected retrospectively from patient charts. Cardiac functional parameters were assessed using magnetic resonance imaging. Results showed that renal function was normal (estimated glomerular filtration rate ≥90 mL/min/1.73 m(2)) in 8 of 10 patients prior to agalsidase alfa and generally remained stable after the switch. Cardiac mass decreased significantly (p < 0.05 vs pre-ERT) after agalsidase beta and remained unchanged after switching to agalsidase alfa. Symptoms of pain and health status scores did not deteriorate during agalsidase alfa therapy. Adverse events were mostly mild and infusion related. In conclusion, switching to agalsidase alfa was relatively well tolerated and associated with stable clinical status and preserved renal and cardiac function.

6.
G Chir ; 32(4): 188-93, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21554849

ABSTRACT

BACKGROUND: The ingestion of caustic substances is one of the most difficult conditions to be treated in Emergency Department. PATIENTS AND METHODS: The medical records of patients with caustic ingestion and hospitalized from 2003 to 2008 at the Division of General Emergency Surgery with Polyspecialistic Observation of AORN "A. Cardarelli "in Naples, have been revalued. RESULTS: From 2003 to 2008, 58 patients with caustic ingestion were admitted to our Division. Ten of these patients (17.24%) underwent surgery. Six patients underwent oesophageal and gastric resection with cervical esophagostomy and alimentary digiunostomy in emergency; two underwent exploratory laparotomy, two had gastroenteroanastomosis for antropyloric stenosis. One patient underwent new operation for a complication. In total, three reconstructions of oesophagus with colon were performed . Of the six patients undergoing esofagogastrectomy, two died in the first postoperative day, but four have passed the acute phase. CONCLUSIONS: There is no universally accepted diagnostic and therapeutic procedure for the management of these patients, who are often left - as it appears in literature - to the personal experience of the surgeon who is dealing with this situation.


Subject(s)
Burns, Chemical/surgery , Caustics/toxicity , Upper Gastrointestinal Tract/injuries , Upper Gastrointestinal Tract/surgery , Female , Humans , Male
7.
Minerva Endocrinol ; 36(4): 295-310, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22322653

ABSTRACT

Gastrointestinal disorders are strictly related to the ovary function. In fact, it is noted that the prevalence of visceral pain disorders such as irritable bowel syndrome, gastroesophageal reflux disease, gallbladder and biliary tract diseases are significantly higher in women. Furthermore, symptom such as nausea, vomiting, abdominal pain, distension, satiety, bloating, diarrhoa or constipation, frequently appears in relation with pregnancy, luteal phase of the menstrual cycle or perimenopausal and menopausal states. Further support for the contribution of ovarian steroids to functional gastrointestinal disorders comes from studies demonstrating that pharmacological ovariectomy reduces abdominal pain symptoms. Therefore, addressing the influence of sex and sex hormones in the modulation of visceral pain appears critical to develop new strategies of diagnosis and therapy sex-directed for gastro-intestinal disorders.


Subject(s)
Gastrointestinal Diseases/physiopathology , Gastrointestinal Motility/physiology , Gonadal Steroid Hormones/physiology , Ovary/physiology , Amygdala/physiopathology , Animals , Combined Modality Therapy , Contraceptives, Oral, Hormonal/therapeutic use , Disease Susceptibility , Emotions , Esophageal Motility Disorders/epidemiology , Esophageal Motility Disorders/etiology , Esophageal Motility Disorders/physiopathology , Estradiol/pharmacology , Estradiol/toxicity , Female , Gallbladder Diseases/etiology , Gallbladder Diseases/physiopathology , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/psychology , Gastrointestinal Hormones/physiology , Gastrointestinal Motility/drug effects , Hormone Replacement Therapy/adverse effects , Humans , Menopause , Menstrual Cycle , Ovary/physiopathology , Pregnancy , Pregnancy Complications/physiopathology , Rats , Sex Distribution , Visceral Pain/etiology , Visceral Pain/physiopathology
8.
Int J Toxicol ; 21(4): 277-85, 2002.
Article in English | MEDLINE | ID: mdl-12171629

ABSTRACT

The potential cancer preventive efficacy of soy isoflavones is being investigated in preclinical and phase 1 clinical studies sponsored by the U.S. National Cancer Institute. Although 90-day oral toxicity studies with PTI G-2535 (an investigational soy isoflavone drug product) in rats and dogs, as well as teratology studies, indicated no signs of toxicity, there remains a mechanistic concern associated with the ability of isoflavones (i.e., genistein) to inhibit topoisomerase, possibly leading to DNA strand breaks. The present report describes results from two in vitro genotoxicity studies, one in vivo genotoxicity study, and a single carcinogenicity study conducted in p53 knockout mice. Bacterial mutagenesis experiments using six tester strains without metabolic activation revealed no evidence that PTI G-2535 was mutagenic. In similar experiments with exogenous metabolic activation there were statistically significant increases in revertants, but less than twofold, in a single (Salmonella typhimurium TA100) tester strain. Mouse lymphoma cell mutagenesis experiments conducted with and without metabolic activation revealed statistically significant increases in mutation frequency at PTI G-2535 concentrations > or = 0.8 and 12 microg/ml, respectively; such increases were dose related and increases in the frequency of both small and large colonies were observed. A statistically significant increase in the frequency of micronucleated polychromatic erythrocytes was also seen 24 hours after treatment in male, but not female, mice who received 500 and 1000 mg/kg body weight PTI G-2535; however,such increases were small, were not dose related, and were not observed 48 hours after treatment. In contrast, dietary genistein had no effect on survival, weight gain, or the incidence or types of tumors that developed in cancer-prone rodents lacking the p53 tumor suppressor gene, p53 knockout mice. The apparent risk/benefit of isoflavone ingestion may ultimately depend on the dose and developmental timing of exposure.


Subject(s)
Carcinogens/toxicity , Genistein/toxicity , Lymphoma/genetics , Mutagens/toxicity , Neoplasms, Experimental/genetics , Administration, Oral , Animals , Bone Marrow Cells/drug effects , Carcinogenicity Tests , Escherichia coli/drug effects , Escherichia coli/genetics , Female , Lymphoma/chemically induced , Lymphoma/pathology , Male , Mice , Mice, Knockout , Micronucleus Tests , Mutation , Neoplasms, Experimental/chemically induced , Neoplasms, Experimental/pathology , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics
9.
Mutagenesis ; 17(3): 201-9, 2002 May.
Article in English | MEDLINE | ID: mdl-11971990

ABSTRACT

ISIS 2302, a phosphorothioate oligodeoxynucleotide with antisense activity against human ICAM-1 mRNA, was evaluated in a battery of tests to assess genotoxic potential. There was no evidence of genotoxicity in three in vitro studies performed: (i) a bacterial reverse mutation test; (ii) a chromosomal aberration test in Chinese hamster ovary cells; (iii) a mammalian cell gene mutation assay in L5187Y cells. Additionally, there was no in vivo evidence of genetic toxicity in a bone marrow micronucleus study in male and female mice. For all tests, top concentrations or doses assessed met harmonized regulatory guidelines. The cellular uptake of ISIS 2302 into target cells was confirmed using capillary gel electrophoresis and immunohistochemistry. Intracellular uptake into CHO cells, L5187Y cells, Salmonella typhimurium TA98 and bone marrow was concentration- and time-dependent. Consistent with what is known about the physical and chemical properties of phosphorothioate oligodeoxynucleotides, there was no evidence of genotoxicity in any of the assessed end-points. Furthermore, the absence of genotoxicity could not be ascribed to test system insensitivity or to an absence of exposure of the test system to ISIS 2302.


Subject(s)
DNA/drug effects , Immunosuppressive Agents/toxicity , Oligodeoxyribonucleotides, Antisense/toxicity , Oligonucleotides/toxicity , Thionucleotides/toxicity , Animals , Bone Marrow/drug effects , CHO Cells , Chromosome Aberrations , Chromosomes/drug effects , Cricetinae , Dose-Response Relationship, Drug , Electrophoresis, Capillary , Female , Immunohistochemistry , Male , Mice , Models, Chemical , Mutation , Phosphorothioate Oligonucleotides , RNA, Messenger/metabolism , Salmonella typhimurium/metabolism , Time Factors
10.
Int Immunopharmacol ; 1(12): 2131-41, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11710542

ABSTRACT

We investigated the immunohematoxicities of the antiparasitic drug dapsone (DDS) and the antiretroviral drug zidovudine (ZDV, AZT) given alone or in combination in BALB/c mice. DDS is used for prophylaxis and treatment of Pneumocystis carinii infection in AIDS patients. We examined the impact of concurrent administration of these drugs on the immune and hematopoietic systems because DDS causes hematotoxicity and ZDV therapy results in bone marrow toxicity. Daily oral administration of DDS at 25 and 50 mg/kg for 28 days caused a slight anemia, marked methemoglobinemia, reticulocytosis, and a moderate leukopenia (P < 0.01 for all parameters) but had no discernible effect on platelet count. In DDS-treated mice, the proliferative response of splenic T cells to concanavalin A was > or = 35% higher than that manifested by splenocytes from vehicle-treated control mice. ZDV at 240 and 480 mg/kg was not immunosuppressive but caused low-grade macrocytic anemia, thrombocytosis, and neutropenia; these effects were drug dose-dependent and statistically significant (P < 0.01). Concurrent administration of DDS and ZDV augmented the severity of ZDV-mediated macrocytic anemia, and 7 of 12 (58%) mice did not survive treatment with the high doses of DDS and ZDV (50 and 480 mg/kg, respectively). On the other hand, co-administration of ZDV mitigated DDS-induced methemoglobinemia and the DDS-associated elevation in lymphoproliferative response. These data suggest interaction between DDS and ZDV in mice and indicate a need for caution in using DDS as long-term therapy in AIDS patients receiving ZDV.


Subject(s)
Anemia/chemically induced , Anti-HIV Agents/toxicity , Antiprotozoal Agents/toxicity , Dapsone/analogs & derivatives , Dapsone/toxicity , Leukopenia/chemically induced , Methemoglobinemia/chemically induced , Thrombocytosis/chemically induced , Zidovudine/toxicity , AIDS-Related Opportunistic Infections/prevention & control , Animals , Anti-HIV Agents/administration & dosage , Antiprotozoal Agents/administration & dosage , Bone Marrow/drug effects , Concanavalin A/pharmacology , Dapsone/administration & dosage , Dapsone/blood , Dose-Response Relationship, Drug , Drug Interactions , Female , Lymph Nodes/drug effects , Lymphocyte Activation/drug effects , Mice , Mice, Inbred BALB C , Neutropenia/chemically induced , Pneumonia, Pneumocystis/prevention & control , Thymus Gland/drug effects , Zidovudine/administration & dosage
11.
Dig Dis ; 19(2): 158-63, 2001.
Article in English | MEDLINE | ID: mdl-11549826

ABSTRACT

BACKGROUND/AIM: Aim of the present study is to assess, according to the guidelines of the Maastricht Consensus Conference, the appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system, in order to evaluate the diffusion of knowledge about Helicobacter pylori among different types of physicians. METHODS: Patients undergoing endoscopy because of dyspeptic symptoms were prospectively considered in 21 endoscopy services of Campania during two different 1-week periods in 1998 and 2001. The following data were recorded: age, sex, symptoms, history of peptic ulcer with regard to previous endoscopic or radiographic examinations and treatment, endoscopic diagnosis, and H. pylori status. The indication for endoscopy was evaluated according to Maastricht guidelines and current medical knowledge. RESULTS: In the two periods, 1998 and 2001, 706 and 520 patients were, respectively, considered. The two series were matched for demographic characteristics, symptoms, and endoscopic diagnosis. Endoscopy was considered not indicated in 398 patients (56.4%) in 1998 and in 265 patients (50.9%) in 2001 (p = NS). The majority of them, 288/398 (72.3%) in 1998 and 162/265 (61.1%) in 2001 (p = 0.001), had recently undergone endoscopy or radiology and empiric antisecretory treatment or eradication. They had been referred to endoscopy because of recurrence of symptoms or to assess healing. In 110 cases in 1998 (27.6%) and in 103 cases in 2001 (38.9%; p = 0.001) endoscopy was performed in dyspeptic patients younger than 45 years without alarm symptoms. CONCLUSIONS: 4 years after the Maastricht Conference, a large number of endoscopic examinations are not indicated and could be avoided following the Maastricht guidelines. In 2001, in comparison to 1998, a larger number of physicians are likely to investigate and treat correctly the H.-pylori-related diseases, but there are still some problems with the application of the 'test-and-treat policy'.


Subject(s)
Diffusion of Innovation , Endoscopy, Gastrointestinal , Guideline Adherence , Helicobacter Infections/diagnosis , Practice Guidelines as Topic , Adolescent , Adult , Aged , Aged, 80 and over , Female , Health Care Surveys , Health Knowledge, Attitudes, Practice , Helicobacter Infections/drug therapy , Helicobacter Infections/pathology , Helicobacter pylori/pathogenicity , Humans , Male , Middle Aged , Physician's Role
12.
Endoscopy ; 33(8): 692-6, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11490386

ABSTRACT

BACKGROUND AND STUDY AIMS: Ingestion of foreign bodies is a common occurrence. Few papers in the literature report experience and outcome at tertiary centers. The aim of this paper is to report the management and the outcomes in 414 patients admitted for suspected ingestion of foreign body between May 1995 and December 1999. METHODS: A plain radiographic film of the neck, chest or abdomen was obtained in the case of radiopaque objects, and in order to rule out suspected perforation: in such cases a computed tomography (CT) study was also performed. All patients were asked to give their informed consent, which was refused by three patients. Anesthesia was always used, either conscious sedation (86.8 %), or general anesthesia in the case of poor patient tolerance (13.2 %). All patients underwent an endoscopic procedure within six hours of admission. A flexible scope was used in all patients and a wide range of endoscopic devices was employed. RESULTS: Foreign bodies were found in 64.5 % of our patients. Almost all were found in the esophagus. The types of foreign body were very different, but they were chiefly food boluses, bones or cartilages, dental prostheses or fish bones. In three patients (1.1 %) it was impossible to endoscopically remove the foreign body, which was located in the cervical esophagus: all these three patients required surgery. No complications relating to the endoscopic procedure were observed, but 30.7 % of patients had an underlying esophageal disease, such as a stricture. Only eight patients required a second endoscopic procedure, performed by a more experienced endoscopist. CONCLUSION: Foreign body ingestion represents a frequent reason for emergency endoscopy. The endoscopic procedure is a successful technique which allows the removal of the foreign bodies in almost all cases without significant complications. Surgery is rarely required.


Subject(s)
Digestive System , Endoscopy, Gastrointestinal , Foreign Bodies/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Digestive System/diagnostic imaging , Emergency Treatment , Female , Foreign Bodies/diagnosis , Humans , Male , Middle Aged , Risk Factors , Tomography, X-Ray Computed
13.
Environ Mol Mutagen ; 38(1): 69-79, 2001.
Article in English | MEDLINE | ID: mdl-11473390

ABSTRACT

AQ-13 ([N1-(7-chloro-quinolin-4yl)-3-(N3,N3-diethylamino)propylamine] dihydrochloride trihydrate) is an aminoquinoline antimalarial drug that is effective against chloroquine-resistant strains of Plasmodium falciparum. It is structurally similar to the widely used chloroquine diphosphate (CQ). We evaluated these drugs in the three assays currently recommended by the International Conference on Harmonization (ICH): bacterial mutagenesis in Salmonella typhimurium and Escherichia coli, mammalian cell mutagenesis in L5178Y mouse lymphoma cells, and micronucleus induction in rat bone marrow. A small but statistically significant increase in revertant colonies was produced by CQ with Salmonella tester strain TA98 without metabolic activation (MA) and by AQ-13 with strain TA1537 both with and without MA. In L5178Y cells, testing of CQ and AQ-13 up to cytotoxic concentrations with and without MA produced no increase in mutant colonies and no increase in the numbers of small colonies. Slight decreases in the ratio of polychromatic erythrocytes (PCE) to red blood cells (RBC) were observed in male and female rats treated with CQ and in females only treated with AQ-13; however, none of these changes was statistically significant. No increases in the frequency of micronucleated PCE were observed at any dose level of CQ or AQ-13. Although both CQ and AQ-13 showed weak bacterial mutagenicity, this mutagenic effect was not confirmed in either the mouse lymphoma mutagenesis assay or the micronucleus assay. These results indicate that CQ and AQ-13 should pose minimal risk of genotoxic damage in human populations being administered these drugs.


Subject(s)
Antimalarials/toxicity , Chloroquine/toxicity , Quinolines/toxicity , Animals , Chloroquine/analogs & derivatives , Mice , Mutagenicity Tests , Rats , Rats, Sprague-Dawley , Salmonella typhimurium/genetics , Toxicity Tests , Tumor Cells, Cultured
14.
Mutat Res ; 455(1-2): 61-9, 2000 Nov 20.
Article in English | MEDLINE | ID: mdl-11113467

ABSTRACT

The Escherichia coli WP2 tryptophan reverse mutation assay detects trp(-) to trp(+) reversion at a site blocking a step in the biosynthesis of tryptophan prior to the formation of anthranilic acid. The different WP2 strains all carry the same AT base pair at the critical mutation site within the trpE gene. The assay is currently used by many laboratories in conjunction with the Ames Salmonella assay for screening chemicals for mutagenic activity. In general the WP2 strains are used as a substitute for, or as an addition to Salmonella strain TA102 which also carries an AT base pair at the mutation site. The assay is also recommended together with the Ames assay for data submission to regulatory agencies. National and international guidelines have been established for performing these mutagenicity assays. The E. coli WP2 assay procedures are the same as those described elsewhere in this volume for the Ames Salmonella assay (Mortelmans and Zeiger, 2000) with the exception that limited tryptophan instead of limited histidine is used. This chapter is an addendum to the previous chapter and the reader should refer to the previous chapter for details regarding experimental procedures and assay design.


Subject(s)
Escherichia coli/drug effects , Mutagenicity Tests/methods , Mutagens/toxicity , Tryptophan/metabolism
15.
Pediatr Med Chir ; 20(4): 261-2, 1998.
Article in Italian | MEDLINE | ID: mdl-9866848

ABSTRACT

The authors have studied two cases of renal tubular acidosis in 2 children underlining that a possible defective mechanism of growth is based on alteration of the receptors of somatomedine C to level of cartilage. The deficit of receptors could be the consequence of the alterations of the acidosis on cartilage.


Subject(s)
Acidosis, Renal Tubular/etiology , Growth Disorders/etiology , Acidosis, Renal Tubular/blood , Acidosis, Renal Tubular/diagnosis , Child, Preschool , Diagnosis, Differential , Female , Growth Disorders/blood , Growth Disorders/diagnosis , Humans , Infant , Insulin-Like Growth Factor I/analysis , Male
16.
Pediatr Med Chir ; 20(4): 275-6, 1998.
Article in Italian | MEDLINE | ID: mdl-9866851

ABSTRACT

In the review, the authors describe the lesions of the oral cavity, which are present in lupus erythematosus, scleroderma, dermatomyositis. They underline the importance of their knowledge for the dentist and for the pediatrician, because the last recognition can influence prognosis negatively.


Subject(s)
Collagen Diseases/diagnosis , Mouth Diseases/diagnosis , Adolescent , Anti-Inflammatory Agents/therapeutic use , Child , Collagen Diseases/complications , Collagen Diseases/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Mouth Diseases/drug therapy , Mouth Diseases/etiology
17.
Toxicol Sci ; 42(2): 91-8, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9579021

ABSTRACT

Increased mortality has been observed when HIV-infected patients were treated with pyrimethamine (Pyr) as prophylaxis for toxoplasmic encephalitis, suggesting that Pyr might possess immunosuppressive activity. To analyze this in an animal model, immune function was assessed in BALB/c mice using a battery of in vivo and ex vivo assays and an in vivo model of host resistance to Listeria monocytogenes infection. Treatment for 30 days with 60 mg/kg Pyr decreased circulating white blood cell and lymphocyte counts but not neutrophil, red blood cell, or platelet counts or hemoglobin levels. Splenic B cell percentages and lipopolysaccharide-induced B cell proliferation decreased significantly after treatment with 60 mg/kg Pyr, as did levels of anti-keyhole limpet hemocyanin (KLH) IgM in serum 7 days after immunization with KLH. Anti-KLH IgG levels 14 days after immunization were not affected. Percentages of splenic T cells and macrophages and T cell proliferation in the presence of concanavalin A or allogeneic cells were not decreased by Pyr treatment. An ex vivo assay of T-cell-mediated cytotoxicity was also unaffected. When host resistance to L. monocytogenes infection was assessed, dramatic increases in mortality were observed in Pyr-treated compared to control mice. Increased numbers of L. monocytogenes organisms were observed in liver and spleen of Pyr-treated mice, compared to controls. The reduction in Listeria resistance, which is T cell mediated, contrasts with the fact that no significant changes in T-cell-mediated immunity were observed. It is possible that Pyr affects parameters of innate immunity, which were not monitored in this study.


Subject(s)
Listeriosis/immunology , Pyrimethamine/toxicity , Animals , Disease Susceptibility/immunology , Dose-Response Relationship, Drug , Female , Listeria monocytogenes/isolation & purification , Listeriosis/mortality , Liver/microbiology , Lymphocyte Subsets , Mice , Mice, Inbred BALB C , Spleen/microbiology
18.
Pediatr Med Chir ; 19(4): 265-6, 1997.
Article in Italian | MEDLINE | ID: mdl-9508652

ABSTRACT

The Authors studied 8 patients with an average age of eight and a half affected with G.N.A.P.S. with "minimum urinary signs". A renal ecography carried out in a diagnostic approach showed in 7 cases out of 8 the constant presence of an increased volume of the kidney, associated with hyperecogenicity and 3rd degree thickening of the cortical. They conclude that this information could be of great use for a rapid diagnostic orientation in forms of G.N.A.P.S. "with minimum urinary signs".


Subject(s)
Glomerulonephritis/diagnostic imaging , Glomerulonephritis/microbiology , Kidney/diagnostic imaging , Streptococcal Infections/diagnostic imaging , Child , Diagnosis, Differential , Humans , Ultrasonography
19.
Pediatr Med Chir ; 19(4): 267-8, 1997.
Article in Italian | MEDLINE | ID: mdl-9508653

ABSTRACT

The above mentioned after a careful investigation of the modern pathogenic aspects of Bartter's syndrome, evaluated the markers that are useful for the prenatal diagnosis of Bartter's syndrome, they pointed out, as in both cases the presence of polyhydramnios not associated with ecographically detectable fetal malformations, elevated chloride in the amniotic fluid, accompanied in one case by increased levels of aldosterone, in the other case by the increase of K, as being reliable markers for the prenatal diagnosis of these conditions.


Subject(s)
Amniotic Fluid/metabolism , Bartter Syndrome/diagnosis , Electrolytes/metabolism , Fetal Diseases/diagnosis , Polyuria/etiology , Bartter Syndrome/complications , Bartter Syndrome/metabolism , Diagnosis, Differential , Female , Fetal Diseases/metabolism , Humans , Infant, Newborn , Male , Polyuria/metabolism
20.
Mutat Res ; 335(3): 207-11, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8524334

ABSTRACT

Tetranitroazoxytoluenes are polynitroaromatic compounds that can be produced during the microbial reduction of the explosive, 2,4,6-trinitrotoluene (TNT). The three major tetranitroazoxytoluenes were synthesized and tested in Salmonella typhimurium strains TA100 and TA100NR. All compounds were mutagenic in TA100 but not in TA100NR, indicating the need for nitroreductase activity to induce mutagenicity. The most active chemical was 4,4',6,6'-tetranitro-2,2'-azoxytoluene (2735 rev/mumol) followed by 2',4,6,6'-tetranitro-2',4-azoxytoluene (929 rev/mumol) and 2,2'-6,6'-tetranitro-4,4'-azoxytoluene (320 rev/mumol). These chemicals were more active than the aminodinitrotoluenes (298 rev/mumol for 2-amino-4,6-dinitrotoluene and 115 rev/mumol for 4-amino-2,6-dinitrotoluene) and only 4,4',6,6'-tetranitro-2,2'-azoxytoluene was more active than the parent compound, TNT (1022 rev/mumol).


Subject(s)
Azo Compounds/toxicity , Dinitrobenzenes/toxicity , Mutagens/toxicity , Salmonella typhimurium/drug effects , Trinitrotoluene/toxicity , Azo Compounds/chemical synthesis , Dinitrobenzenes/chemical synthesis , Mutagenesis/drug effects , Mutagenicity Tests , Salmonella typhimurium/genetics , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...